◆英語タイトル:Apogenix AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011801
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月13日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Apogenix AG (Apogenix) is a biopharmaceutical company, developing immuno-oncology medicines for the treatment of cancer and other malignant diseases. Its pipeline drug candidates under clinical development include Asunercept (APG101), a CD95 ligand inhibitor, for the treatment of glioblastoma and myelodysplastic syndromes. Apogenix has also developed the proprietary HERA technology platform for the construction of novel hexavalent (TNFSF) receptor agonists for the treatment of cancer. It also conducts preclinical and clinical studies for various tumor indications. The company works in partnership with other pharmaceutical and biotechnology companies as well as collaborates with leading academic institutions for the preclinical, clinical development and commercialization of its proprietary drug candidates. Apogenix is headquartered Heidelberg, Germany.
Apogenix AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Apogenix AG, Medical Devices Deals, 2011 to YTD 2017 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Apogenix AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Apogenix Secures US$9.8 Million In Venture Financing 11
Licensing Agreements 12
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG – Key Competitors 14
Apogenix AG – Key Employees 15
Apogenix AG – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
09/26/2016: First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan 17
Sep 13, 2017: CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 18
Mar 20, 2017: Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR) 19
02/16/2016: Apogenix Receives EUR3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101 21
01/07/2016: Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan 22
Product Approvals 23
Jul 26, 2016: CANbridge CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan 23
Apr 07, 2016: CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma 24
Clinical Trials 25
Nov 03, 2016: Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition 25
Jun 15, 2016: Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101 26
Mar 24, 2016: Preclinical Efficacy Data of Apogenix’ APG101 in Myelodysplastic Syndromes Published in Oncotarget 27
Jan 07, 2016: CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List of Tables
Apogenix AG, Pharmaceuticals & Healthcare, Key Facts 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Apogenix AG, Deals By Therapy Area, 2011 to YTD 2017 8
Apogenix AG, Medical Devices Deals, 2011 to YTD 2017 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Apogenix Secures US$9.8 Million In Venture Financing 11
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG, Key Competitors 14
Apogenix AG, Key Employees 15